Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/21645515.2015.1037058 http://scihub22266oqcxt.onion/10.1080/21645515.2015.1037058 C4514197!4514197!25996182     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hum+Vaccin+Immunother 2015 ; 11 (7): 1573-84 Nephropedia Template TP {{tp|p=25996182|t=2015. Oncolytic viruses: From bench to bedside with a focus on safety |pdf=|usr=}}{{25996182}} gab.com Text Oncolytic viruses: From bench to bedside with a focus on safety JO: Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=25996182 #FOAvip Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current review, an overview is presented on recent (pre)clinical developments in the field of oncolytic viruses that have previously been or currently are being evaluated in clinical trials. Special attention is given to possible safety issues like toxicity, environmental shedding, mutation and reversion to wildtype virus. Twit Text FOAVip Oncolytic viruses: From bench to bedside with a focus on safety ????Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=25996182 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25996182 #FOAvip English Wikipedia <ref>{{Cite pmid|25996182}}</ref> Oncolytic viruses: From bench to bedside with a focus on safety #MMPMID25996182 Buijs PR; Verhagen JH; van Eijck CH; van den Hoogen BG Hum Vaccin Immunother 2015[Jul]; 11 (7): 1573-84 PMID25996182show ga Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current review, an overview is presented on recent (pre)clinical developments in the field of oncolytic viruses that have previously been or currently are being evaluated in clinical trials. Special attention is given to possible safety issues like toxicity, environmental shedding, mutation and reversion to wildtype virus. äOncolytic viruses: From bench to bedside with a focus on safety (epmc).pdf DeepDyve Pubget Overpricing